{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:19:35Z","timestamp":1788182375754,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15938 and 25K12855"],"award-info":[{"award-number":["23K15938 and 25K12855"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer Retina Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Retinal pigment epithelial and outer retinal atrophy (RORA) and complete RORA (cRORA) are major determinants of long-term vision in neovascular age-related macular degeneration (nAMD), but their development across subtypes is poorly defined, especially in Asian populations, in whom pachychoroid-driven disease is common. We compared long-term visual outcomes and atrophy burden between the conventional and novel nAMD classifications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One hundred twenty eyes of 120 treatment-na\u00efve patients with nAMD followed at least six years were classified by conventional (typical nAMD [tAMD], polypoidal choroidal vasculopathy [PCV], retinal angiomatous proliferation [RAP]) and novel (drusen type, pachychoroid type, mixed type, other type) schemes. All eyes received three loading anti-VEGF injections followed by a pro re nata regimen. RORA within the central 1\u00a0mm was graded on optical coherence tomography; lesions\u2009\u2265\u2009250\u00a0\u03bcm were defined as cRORA. Visual acuity (VA) retention, atrophy prevalence, and VA around atrophy onset were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean age was 78.0\u2009\u00b1\u20099.2 years and overall VA retention was 71%. VA retention did not differ among conventional subtypes, but under the novel classification was significantly lower in the drusen type and higher in the pachychoroid type (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). VA declined significantly after both RORA and cRORA onset (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Final RORA\/cRORA prevalence was 44.4%\/29.6% in tAMD, 50.0%\/28.3% in PCV, 83.3%\/50.0% in RAP and 76.9%\/61.5% in the drusen type, in which cRORA was highest (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The novel classification distinguished long-term visual outcomes that the conventional classification did not: the drusen type showed the poorest VA retention and highest cRORA prevalence, whereas the pachychoroid type fared best.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-05255-0","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:46:08Z","timestamp":1787553968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term visual outcomes and development of retinal pigment epithelial and outer retinal atrophy in neovascular age-related macular degeneration: a comparison of conventional and novel classifications"],"prefix":"10.1186","volume":"26","author":[{"given":"Debabrata","family":"Hazra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kunimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuno","family":"Negishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"5255_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"5255_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33:14\u201333.","journal-title":"Eye (Lond)"},{"key":"5255_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying G, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"5255_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566\u201383.","journal-title":"Am J Ophthalmol"},{"key":"5255_CR5","doi-asserted-by":"publisher","first-page":"9275","DOI":"10.1038\/s41598-021-88543-7","volume":"11","author":"DD-J Hwang","year":"2021","unstructured":"Hwang DD-J, Choi S, Ko J, Yoon J, Park JI, Hwang JS, et al. Distinguishing retinal angiomatous proliferation from polypoidal choroidal vasculopathy with a deep neural network based on optical coherence tomography. Sci Rep. 2021;11:9275.","journal-title":"Sci Rep"},{"key":"5255_CR6","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41598-022-05903-7","volume":"12","author":"J Han","year":"2022","unstructured":"Han J, Choi S, Park JI, Hwang JS, Han JM, Lee HJ, et al. Classifying neovascular age-related macular degeneration with a deep convolutional neural network based on optical coherence tomography images. Sci Rep. 2022;12:2232.","journal-title":"Sci Rep"},{"key":"5255_CR7","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","volume":"33","author":"DJ Warrow","year":"2013","unstructured":"Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659\u201372.","journal-title":"Retina"},{"key":"5255_CR8","doi-asserted-by":"publisher","first-page":"e0261320","DOI":"10.1371\/journal.pone.0261320","volume":"16","author":"M Saito","year":"2021","unstructured":"Saito M, Iida T, Saito K, Kano M, Itagaki K. Long-term characteristics of exudative age- related macular degeneration in Japanese patients. PLoS ONE. 2021;16:e0261320.","journal-title":"PLoS ONE"},{"key":"5255_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10384-020-00740-5","volume":"64","author":"Y Yanagi","year":"2020","unstructured":"Yanagi Y. Pachychoroid disease: a new perspective on exudative maculopathy. Jpn J Ophthalmol. 2020;64:323\u201337.","journal-title":"Jpn J Ophthalmol"},{"key":"5255_CR10","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00417-022-05625-6","volume":"260","author":"HM Kim","year":"2022","unstructured":"Kim HM, Ryoo N-K, Park KH. Laser and anti-vascular endothelial growth factor treatment for drusenoid pigment epithelial detachment in age-related macular degeneration: 24-month outcomes. Graefes Arch Clin Exp Ophthalmol. 2022;260:2549\u201359.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5255_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ophtha.2019.09.035","volume":"127","author":"RH Guymer","year":"2020","unstructured":"Guymer RH, Rosenfeld PJ, Curcio CA, Holz FG, Staurenghi G, Freund KB, et al. Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4. Ophthalmology. 2020;127:394\u2013409.","journal-title":"Ophthalmology"},{"key":"5255_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SVR Sadda","year":"2018","unstructured":"Sadda SVR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018;125:878\u201386.","journal-title":"Ophthalmology"},{"key":"5255_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.oret.2025.01.011","volume":"9","author":"A Berni","year":"2025","unstructured":"Berni A, Coletto A, Li J, Shen M, Bandello F, Reibaldi M, et al. Macular Atrophy in Neovascular Age-related Macular Degeneration: A Systematic Review and Meta-analysis. Ophthalmol Retina. 2025;9:625\u201344.","journal-title":"Ophthalmol Retina"},{"key":"5255_CR14","doi-asserted-by":"publisher","first-page":"100612","DOI":"10.1016\/j.xops.2024.100612","volume":"5","author":"N Nagai","year":"2025","unstructured":"Nagai N, Matsubara H, Terasaki H, Hirano T, Kato A, Miki A, et al. Extent of Complete Retinal Pigment Epithelial and Outer Retinal Atrophy with Foveal Center Involvement is Associated with Visual Acuity. Ophthalmol Sci. 2025;5:100612.","journal-title":"Ophthalmol Sci"},{"key":"5255_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/11206721211001708","volume":"32","author":"MH Ji","year":"2022","unstructured":"Ji MH, Callaway NF, Ludwig CA, Vail D, Al-Moujahed A, Rosenblatt TR, et al. Visual acuity and progression of macular atrophy in patients receiving intravitreal anti-VEGF for age-related macular degeneration. Eur J Ophthalmol. 2022;32:429\u201335.","journal-title":"Eur J Ophthalmol"},{"key":"5255_CR16","doi-asserted-by":"publisher","first-page":"e0232353","DOI":"10.1371\/journal.pone.0232353","volume":"15","author":"VA Eng","year":"2020","unstructured":"Eng VA, Rayess N, Nguyen HV, Leng T. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration. PLoS ONE. 2020;15:e0232353.","journal-title":"PLoS ONE"},{"key":"5255_CR17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"5255_CR18","first-page":"278","volume":"126","author":"S Kato","year":"2024","unstructured":"Kato S, Uchida A, Nagai N, et al. Long-term visual outcomes of anti-VEGF therapies for different subtypes of nAMD. J Jpn Ophthalmol Soc. 2024;126:278.","journal-title":"J Jpn Ophthalmol Soc"},{"key":"5255_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/IAE.0000000000001689","volume":"38","author":"RF Spaide","year":"2018","unstructured":"Spaide RF, DISEASE, EXPRESSION IN NONEXUDATIVE AGE-RELATED MACULAR DEGENERATION VARIES WITH CHOROIDAL THICKNESS. Retina. 2018;38:708\u201316.","journal-title":"Retina"},{"key":"5255_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2018;125:537\u201348.","journal-title":"Ophthalmology"},{"key":"5255_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"5255_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41433-024-03253-4","volume":"39","author":"CMG Cheung","year":"2025","unstructured":"Cheung CMG, Dansingani KK, Koizumi H, Lai TYY, Sivaprasad S, Boon CJF, et al. Pachychoroid disease: review and update. Eye (Lond). 2025;39:819\u201334.","journal-title":"Eye (Lond)"},{"key":"5255_CR23","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.3390\/jcm13092608","volume":"13","author":"N Ban","year":"2024","unstructured":"Ban N, Shinojima A, Negishi K, Kurihara T. Drusen in AMD from the Perspective of Cholesterol Metabolism and Hypoxic Response. J Clin Med. 2024;13:2608.","journal-title":"J Clin Med"},{"key":"5255_CR24","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1007\/s00417-021-05147-7","volume":"259","author":"M Jhingan","year":"2021","unstructured":"Jhingan M, Singh SR, Samanta A, Arora S, Tucci D, Amarasekera S, et al. Drusen ooze: Predictor for progression of dry age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2021;259:2687\u201394.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5255_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00417-021-05419-2","volume":"260","author":"S Amarasekera","year":"2022","unstructured":"Amarasekera S, Samanta A, Jhingan M, Arora S, Singh S, Tucci D, et al. Optical coherence tomography predictors of progression of non-exudative age-related macular degeneration to advanced atrophic and exudative disease. Graefes Arch Clin Exp Ophthalmol. 2022;260:737\u201346.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5255_CR26","doi-asserted-by":"crossref","unstructured":"Nagai N, Shinoda H, Matsubara H, Terasaki H, Hirano T, Kato A et al. Associations between Progression of Retinal Pigment Epithelial and Outer Retinal Atrophy and Choroidal Thickness; Two Years Observation. Ophthalmol Sci. 2025;6:100939.","DOI":"10.1016\/j.xops.2025.100939"},{"key":"5255_CR27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","volume":"121","author":"FG Holz","year":"2014","unstructured":"Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121:1079\u201391.","journal-title":"Ophthalmology"},{"key":"5255_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1350-9462(01)00010-6","volume":"20","author":"GS Hageman","year":"2001","unstructured":"Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch\u2019s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705\u201332.","journal-title":"Prog Retin Eye Res"},{"key":"5255_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0039-6257(00)00140-5","volume":"45","author":"S Beatty","year":"2000","unstructured":"Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115\u201334.","journal-title":"Surv Ophthalmol"},{"key":"5255_CR30","doi-asserted-by":"publisher","first-page":"768026","DOI":"10.1155\/2014\/768026","volume":"2014","author":"J Blasiak","year":"2014","unstructured":"Blasiak J, Petrovski G, Ver\u00e9b Z, Facsk\u00f3 A, Kaarniranta K. Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration. Biomed Res Int. 2014;2014:768026.","journal-title":"Biomed Res Int"},{"key":"5255_CR31","doi-asserted-by":"publisher","first-page":"690243","DOI":"10.1155\/2015\/690243","volume":"2015","author":"J Gao","year":"2015","unstructured":"Gao J, Liu RT, Cao S, Cui JZ, Wang A, To E, et al. NLRP3 inflammasome: activation and regulation in age-related macular degeneration. Mediators Inflamm. 2015;2015:690243.","journal-title":"Mediators Inflamm"},{"key":"5255_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1152\/physrev.00021.2004","volume":"85","author":"O Strauss","year":"2005","unstructured":"Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85:845\u201381.","journal-title":"Physiol Rev"},{"key":"5255_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/IAE.0b013e31827e25e0","volume":"33","author":"CA Curcio","year":"2013","unstructured":"Curcio CA, Messinger JD, Sloan KR, McGwin G, Medeiros NE, Spaide RF. Subretinal drusenoid deposits in non-neovascular age-related macular degeneration: morphology, prevalence, topography, and biogenesis model. Retina. 2013;33:265\u201376.","journal-title":"Retina"},{"key":"5255_CR34","doi-asserted-by":"publisher","first-page":"16204","DOI":"10.1038\/srep16204","volume":"5","author":"M Miyake","year":"2015","unstructured":"Miyake M, Ooto S, Yamashiro K, Takahashi A. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015;5:16204.","journal-title":"Sci Rep"},{"key":"5255_CR35","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1038\/s41598-023-33936-z","volume":"13","author":"A Kuranami","year":"2023","unstructured":"Kuranami A, Maruko R, Maruko I, Hasegawa T, Iida T. Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age \u2013 related macular degeneration. Sci Rep. 2023;13:7379.","journal-title":"Sci Rep"},{"key":"5255_CR36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10384-025-01240-0","volume":"69","author":"T Iida","year":"2025","unstructured":"Iida T, Gomi F, Yasukawa T, Yamashiro K, Honda S, Maruko I. Japanese clinical guidelines for neovascular age \u2013 related macular degeneration. Jpn J Ophthalmol. 2025;69:639\u201360.","journal-title":"Jpn J Ophthalmol"},{"key":"5255_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2022","unstructured":"Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2022;37:6\u201316.","journal-title":"Eye (Lond)"},{"key":"5255_CR38","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ophtha.2019.11.010","volume":"127","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Guymer R, Mon\u00e9s JM, Tufail A, Jaffe GJ. Anti\u2013Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age\u2013Related Macular Degeneration: Systematic Literature Review and Expert Opinion. Ophthalmology. 2020;127:648\u201359.","journal-title":"Ophthalmology"},{"key":"5255_CR39","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41433-021-01487-0","volume":"35","author":"L Kodjikian","year":"2021","unstructured":"Kodjikian L, Parravano M, Clemens A, Dolz-Marco R, Holz FG, Munk MR, et al. Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. Eye (Lond). 2021;35:2119\u201335.","journal-title":"Eye (Lond)"},{"key":"5255_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ceo.14495","volume":"53","author":"PJ Patel","year":"2025","unstructured":"Patel PJ. Treat and Extend Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: To Stop or Not to Stop? Clin Exp Ophthalmol. 2025;53:8\u201310.","journal-title":"Clin Exp Ophthalmol"},{"key":"5255_CR41","unstructured":"Department of Ophthalmology, Keio University School of Medicine. Opt out of the retrospective study. https:\/\/www.ctr.hosp.keio.ac.jp\/patients\/optout\/index.html. Accessed 16 Aug 2021."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05255-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05255-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05255-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:47:13Z","timestamp":1788180433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05255-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5255"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05255-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study adhered to the tenets of the Declaration of Helsinki and was approved by the Keio University School of Medicine Ethics Committee (approval number 20100003). According to ethical guidelines for clinical studies by the Japanese Ministry of Health, Labor and Welfare, written informed consent is not required from patients for studies that do not involve biological tissue and only involve a retrospective review of medical records. Therefore, we displayed our ethical statement and written guidelines for the current research on our website in Japanese [\n                      \n                      ].","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"531"}}